Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

The Lancet Oncology

Volumn 17, Issue 1, 2016, Pages 27-38

  Dimopoulos, Meletios A ^a   Moreau, Philippe ^b   Palumbo, Antonio ^c   Joshua, Douglas ^d   Pour, Ludek ^e   Hájek, Roman ^f   Facon, Thierry ^g   Ludwig, Heinz ^h   Oriol, Albert ⁱ   Goldschmidt, Hartmut ^j   Rosiñol, Laura ^k   Straub, Jan ^l   Suvorov, Aleksandr ^m   Araujo, Carla ⁿ   Rimashevskaya, Elena ^o   Pika, Tomas ^p   Gaidano, Gianluca ^q   Weisel, Katja ^r   Goranova Marinova, Vesselina ^s   Schwarer, Anthony ^t   Minuk, Leonard ^u   Masszi, Tamás ^v   Karamanesht, Ievgenii ^w   Offidani, Massimo ^x   Hungria, Vania ^y   Spencer, Andrew ^z   Orlowski, Robert Z ^aa   Gillenwater, Heidi H ^ab   Mohamed, Nehal ^ab   Feng, Shibao ^ab   Chng, Wee Joo ^ac   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITY OF TURIN   (Italy)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^f UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h WILHELMINEN HOSPITAL   (Austria)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^l CHARLES UNIVERSITY   (Czech Republic)

^m First Republican Clinical Hospital of Udmurtia   (Russian Federation)

ⁿ CENTRE HOSPITALIER DE LA CÔTE BASQUE   (France)

^o N Semashko Hospital   (Russian Federation)

^p UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^q UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^r UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^s Clinic of Dermatology and Venerology   (Bulgaria)

^t BOX HILL HOSPITAL   (Australia)

^u UNIVERSITY OF WESTERN ONTARIO   (Canada)

^v Szent Laszlo Hospital   (Hungary)

^w Kyiv Center of Bone Marrow Transplantation   (Ukraine)

^x OSPEDALI RIUNITI   (Italy)

^y IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

^z MONASH UNIVERSITY   (Australia)

^aa UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ab ONYX PHARMACEUTICALS   (United States)

^ac NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; OLIGOPEPTIDE;

AGED; ANEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SURVIVAL RATE; THROMBOCYTOPENIA;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MULTIPLE MYELOMA; OLIGOPEPTIDES; PNEUMONIA; RETREATMENT; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84955420512     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00464-7     Document Type: Article

References (23)

1. Siegel R, Ma J, Zou Z, Jemal A Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
3. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
4. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
5. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
6. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
7. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006, 91:929-934. SUMMIT/CREST Investigators.
8. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010, 116:4745-4753.
9. Papadopoulos KP, Siegel DS, Vesole DH, et al. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol 2015, 33:732-739.
10. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012, 120:2817-2825.
11. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473. International Myeloma Working Group.
12. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
13. DeMets DL, Lan G The alpha spending function approach to interim data analyses. Cancer Treat Res 1995, 75:1-27.
14. Lan KKG, DeMets DL Discrete sequential boundaries for clinical trials. Biometrika 1983, 70:659-663.
15. Ye Y, Li A, Liu L, Yao B A group sequential Holm procedure with multiple primary endpoints. Stat Med 2013, 32:1112-1124.
16. Lonial S, Anderson KC Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 2014, 28:258-268.
17. Dimopoulos MA, Orlowski RZ, Facon T, et al. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica 2015, 100:100-106.
18. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014, 15:1195-1206.
19. Corso A, Varettoni M, Mangiacavalli S, et al. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived. Eur J Haematol 2009, 83:449-454.
20. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015, 372:142-152. ASPIRE Investigators.
21. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013, 98:1753-1761.
22. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110:3281-3290.
23. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011, 17:2734-2743.